ADVFN - Advanced Financial Network.
HOME» NYSE » A » AGN Stock Price » AGN Stock News

Allergan Share News

 Allergan, Stock Price
AGN Stock Price
 Allergan, Stock Chart
AGN Stock Chart
 Allergan, Stock News
AGN Stock News
 Allergan, Company Information
AGN Company Information
 Allergan, Stock Trades
AGN Stock Trades

Inspire Pharma: Dry-Eye Treatment Didn't Meet Study Endpoints

DOW JONES NEWSWIRES Inspire Pharmaceuticals Inc. (ISPH) said its Prolacria treatment for dry eye met neither the primary nor secondary endpoints in a late-stage trial. Shares fell 7.5% to $6.11 premarket. Shares in its partner in developing the eye drops, Allergan Inc. (AGN), weren't active after closing Wednesday at $61.20. Early data about Prolacria had been discouraging, so the final results won't come as a huge surprise, but the treatment had been one of Inspire's most advanced drugs in its pipeline. Its other advanced drug candidate is denufosol tetrasodium for cystic fibrosis. Inspire focuses on developing treatments for ophthalmic and pulmonary diseases. Chief Executive Christy Shaffer said Inspire has reported the results to Allergan and "will be conducting a thorough review of the program before determining next steps, if any." At the end of the six-week study, Inspire gauged subjects extent of dry eye with a "staining score," in which patterns made by a stain are used to measure damaged cells in the central area of the cornea. It aimed to have a proportion of its subjects receiving Prolacria have a staining score of zero compared to a placebo group, its primary endpoint. It also failed to reduce the staining score by two units compared to the control group, the secondary endpoint. Dry eye occurs when the eye isn't being sufficiently lubricated. In November, the drug company reported a narrower third-quarter loss thanks to double-digit growth in sales. -By Joan E. Solsman, Dow Jones Newswires; 212-416-2291; joan.solsman@dowjones.com

Stock News for Allergan (AGN)
DateTimeHeadline
04/29/201609:24:00Allergan Receives CHMP Positive Opinion For ENZEPI® (Pancrelipase...
04/29/201609:08:00Allergan Receives CHMP Positive Opinion For ENZEPI® (Pancrelipase...
04/26/201607:55:00Allergan Presents Data at the Association for Research in Vision...
04/25/201616:05:00Allergan Breaks Ground on $200 Million Waco Facility Expansion
04/21/201616:30:00Allergan Acquires Topical Dermatology Company Topokine Therapeutics...
04/20/201607:30:00Allergan to Host First Quarter 2016 Earnings Conference Call...
04/19/201617:21:20Additional Proxy Soliciting Materials (definitive) (defa14a)
04/14/201616:13:36Current Report Filing (8-k)
04/13/201608:00:00Allergan Announces 10 Presentations on Chronic Migraine, Upper...
04/08/201607:30:00Allergan Reinforces Commitment to Anti-Infective Innovation with...
04/07/201609:00:00Allergan Completes Licensing Deal After Pfizer Bid Collapses
04/07/201608:49:00Allergan Completes Licensing Deal After Pfizer Bid Collapses
04/07/201604:50:00Global Stocks Mostly Edge Up After Oil Price Rally
04/06/201619:30:00Allergan and Heptares Announce Global R&D and Commercialization...
04/06/201618:30:00FDA Approves Medtronic Device, Billed as World's Smallest Pacemaker
04/06/201617:25:03Withdrawal of Registration Statement (rw)
04/06/201617:20:00Shire: Baxalta Deal Is Still On
04/06/201616:30:00Treasury Has Outsize Legal Leverage on Inversions
04/06/201615:04:00Allergan CEO Saunders Criticizes Treasury Rules That Scuttled...
04/06/201612:16:00Pfizer, Allergan End Merger Agreement -- 2nd Update

Allergan and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad